Literature DB >> 6830338

Plasma fibronectin and associated variables in surgical intensive care patients.

E Rubli, S Büssard, E Frei, P Lundsgaard-Hansen, E Pappova.   

Abstract

An acute depletion of plasma fibronectin or FN has been observed in critically ill, surgical, or trauma patients, but there is little information on the relationships between FN levels and the final outcome in such cases, and on the simultaneous behaviour of other serum proteins. The daily values of FN, antithrombin III, IgG, C3, prealbumin, and transferrin were monitored in 98 intensive care patients after major elective surgery or trauma. According to their clinical course, they were divided retrospectively into three groups. Group A (33 patients) had sepsis. Group B (31 patients) had nonseptic complications, and group C (34 patients) had no complications in the ICU. The individual, nadir levels of FN, AT III, prealbumin, and transferrin were lower (p less than 0.01) in the septic group A than in B and C. Within the septic group, the nadir levels of AT III, but not those of FN, were lower (p less than 0.01) in the 14 nonsurvivors than in the 19 survivors. The FN and AT III levels had returned at least temporarily to the normal range in the six ultimate fatalities from sepsis who survived for more than two weeks. In the septic group, transferrin showed the highest percentages of actually subnormal levels and differed from FN in this respect with p less than 0.05. Furthermore, all six proteins showed a significant overall pattern (p less than 0.01) of parallel variations. The results confirm other reports on the behavior of fibronectin in septic patients as a group, but it was not informative as to the individual outcome, and its reduction might be viewed as part of a general plasma protein depletion associated with acute septic disease. This pattern is probably attributable to a combination of intravascular consumption and an overall excess of protein catabolism over synthesis.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6830338      PMCID: PMC1352735          DOI: 10.1097/00000658-198303000-00011

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  37 in total

1.  Disturbances in circulating opsonic activity in man after operative and blunt trauma.

Authors:  W A Scovill; T M Saba; J E Kaplan; H R Bernard; S R Powers
Journal:  J Surg Res       Date:  1977-06       Impact factor: 2.192

Review 2.  Physiology and physiopathology of the reticuloendothelial system.

Authors:  T M Saba
Journal:  Arch Intern Med       Date:  1970-12

3.  Remote organ failure: a valid sign of occult intra-abdominal infection.

Authors:  H C Polk; C L Shields
Journal:  Surgery       Date:  1977-03       Impact factor: 3.982

4.  Reticuloendothelial systemic response to operative trauma as influenced by cryoprecipitate or cold-insoluble globulin therapy.

Authors:  T M Saba; E Cho
Journal:  J Reticuloendothel Soc       Date:  1979-08

5.  Consumptive opsoninopathy: possible pathogenesis in lethal and opportunistic infections.

Authors:  J W Alexander; M A McClellan; C K Ogle; J D Ogle
Journal:  Ann Surg       Date:  1976-12       Impact factor: 12.969

6.  Opsonic alpha2 surface binding glycoprotein therapy during sepsis.

Authors:  W A Scovill; T M Saba; F A Blumenstock; H Bernard; S R Powers
Journal:  Ann Surg       Date:  1978-10       Impact factor: 12.969

7.  Fibronectin concentration is decreased in plasma of severely ill patients with disseminated intravascular coagulation.

Authors:  D F Mosher; E M Williams
Journal:  J Lab Clin Med       Date:  1978-05

8.  Cryoprecipitate reversal of opsonic alpha2-surface binding glycoprotein deficiency in septic surgical and trauma patients.

Authors:  T M Saba; F A Blumenstock; W A Scovill; H Bernard
Journal:  Science       Date:  1978-08-18       Impact factor: 47.728

9.  Cardiovascular hemodynamics after opsonic alpha-2-surface binding glycoprotein therapy in injured patients.

Authors:  W A Scovill; S J Annest; T M Saba; F A Blumenstock; J C Newell; H H Stratton; S R Powers
Journal:  Surgery       Date:  1979-08       Impact factor: 3.982

10.  Prevention of liver reticuloendothelial systemic host defense failure after surgery by intravenous opsonic glycoprotein therapy.

Authors:  T M Saba
Journal:  Ann Surg       Date:  1978-08       Impact factor: 12.969

View more
  13 in total

1.  Effect of hepatocyte-stimulating factor and glucocorticoids on plasma fibronectin levels.

Authors:  D L Amrani; D Mauzy-Melitz; M W Mosesson
Journal:  Biochem J       Date:  1986-09-01       Impact factor: 3.857

2.  Plasma fibronectin in Crohn's disease.

Authors:  A Allan; J Wyke; R N Allan; P Morel; M Robinson; D L Scott; J Alexander-Williams
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

3.  Fibronectin degradation products containing the cytoadhesive tetrapeptide stimulate human neutrophil degranulation.

Authors:  Y T Wachtfogel; W Abrams; U Kucich; G Weinbaum; M Schapira; R W Colman
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

4.  Impaired host defence mechanisms in intensive care unit patients.

Authors:  W Zimmerli
Journal:  Intensive Care Med       Date:  1985       Impact factor: 17.440

5.  Regulation of fibronectin synthesis by interleukin-1 and interleukin-6 in rat hepatocytes.

Authors:  T Hagiwara; H Suzuki; I Kono; H Kashiwagi; Y Akiyama; K Onozaki
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

6.  Use of antithrombin III in critical patients.

Authors:  J M Díaz-Cremades; R Lorenzo; M Sánchez; M J Moreno; M J Alsar; J M Bosch; L Fajardo; D González; D Guerrero
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

Review 7.  Plasma fibronectin: relevance for anesthesiology and intensive care.

Authors:  J E Doran; P Lundsgaard-Hansen; E Rubli
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

Review 8.  Fibronectin and the critically ill patient: current status.

Authors:  T M Saba; J L Kiener; J M Holman
Journal:  Intensive Care Med       Date:  1986       Impact factor: 17.440

9.  Increased serum fibronectin levels in patients with hemorrhagic fever with renal syndrome.

Authors:  Qunying Han; Wen Kang; Lei Zhang; Sai Lou; Qianzi Zhao; Zhengwen Liu
Journal:  Inflamm Res       Date:  2009-08-22       Impact factor: 4.575

10.  Purified fibronectin administration to patients with severe abdominal infections. A controlled clinical trial.

Authors:  P Lundsgaard-Hansen; J E Doran; E Rubli; E Papp; J J Morgenthaler; P Späth
Journal:  Ann Surg       Date:  1985-12       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.